NYSE: OHI
OMEGA HEALTHCARE INVESTORS INCCIK 0000888491 · SIC 6798 · Real Estate Investment Trusts
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (DLTH 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade OHI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Omega Healthcare holds annual meeting; all directors elected, say-on-pay approved at 95%
5 material changes detected. Sign up free to read the summary.
Omega Healthcare announces CEO and CFO departures in planned leadership transition
5 material changes detected. Sign up free to read the summary.
revenue $323.0M, net income $151.0M. Omega adopts RIDEA operating model, faces Medicaid cuts, extends Genesis DIP loan
5 material changes detected. Sign up free to read the summary.
Omega Healthcare Investors reports Q1 2026 earnings results
1 material change detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 30, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | ||||
| Rental income | 266,486 | 239,202 | 537,103 | 471,380 |
| Interest income | 46,756 | 42,997 | 91,911 | 86,113 |
| Resident fees and services | 13,987 | — | 20,644 | — |
| Miscellaneous income | 1,017 | 307 | 1,543 | 1,798 |
| Total revenues | 328,246 | 282,506 | 651,201 | 559,291 |
| Expenses | ||||
| Depreciation and amortization | 81,842 | 80,509 | 165,982 | 160,384 |
| Interest expense | 48,116 | 52,897 | 97,871 | 105,177 |
| Property-level expenses | 16,197 | 3,771 | 25,640 | 7,597 |
| General and administrative | 41,997 | 23,318 | 67,584 | 54,860 |
| Acquisition, merger and transition related costs | 4,660 | 2,010 | 5,774 | 3,474 |
| Impairment on real estate properties | — | 14,215 | 392 | 15,450 |
| (Recovery) provision for credit losses | (5,019) | (4,771) | (8,313) | 321 |
| Total expenses | 187,793 | 171,949 | 354,930 | 347,263 |
| Other income (expense) | ||||
| Other (expense) income net | (7,215) | 13,751 | (6,139) | 16,798 |
| Gain on assets sold net | 246,519 | 22,886 | 249,543 | 32,961 |
| Total other income | 239,304 | 36,637 | 243,404 | 49,759 |
| Income before income tax expense and income (loss) from unconsolidated entities | 379,757 | 147,194 | 539,675 | 261,787 |
| Income tax expense | (4,618) | (4,528) | (9,724) | (8,139) |
| Income (loss) from unconsolidated entities | 4,529 | (2,187) | 8,293 | (1,109) |
| Net income | 379,668 | 140,479 | 538,244 | 252,539 |
| Net income attributable to noncontrolling interest | (16,845) | (3,880) | (24,372) | (6,908) |
| Net income available to common stockholders | 362,823 | 136,599 | 513,872 | 245,631 |
| Earnings per common share available to common stockholders: | ||||
| Basic: | ||||
| Net income available to common stockholders | 1.21 | 0.46 | 1.68 | 0.80 |
| Diluted: | ||||
| Net income available to common stockholders | 1.19 | 0.46 | 1.66 | 0.79 |
Consolidated Balance Sheets
(in thousands, except per share amounts)
| Description | June 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Real estate assets | ||
| Buildings and improvements | 7,731,936 | 7,901,652 |
| Land | 1,177,340 | 1,179,463 |
| Furniture and equipment | 534,282 | 539,775 |
| Construction in progress | 16,789 | 12,492 |
| Total real estate assets | 9,460,347 | 9,633,382 |
| Less accumulated depreciation | (2,991,978) | (2,930,611) |
| Real estate assets net | 6,468,369 | 6,702,771 |
| Real estate loans receivable net | 1,366,744 | 1,380,949 |
| Investments in unconsolidated entities | 501,217 | 414,127 |
| Assets held for sale | — | 4,000 |
| Total real estate investments | 8,336,330 | 8,501,847 |
| Non-real estate loans receivable net | 270,166 | 330,322 |
| Total investments | 8,606,496 | 8,832,169 |
| Cash and cash equivalents | 39,036 | 27,024 |
| Restricted cash | 145,173 | 27,539 |
| Contractual and other receivables net | 276,092 | 280,774 |
| Goodwill | 644,441 | 644,626 |
| Other assets | 303,523 | 236,927 |
| Total assets | 10,014,761 | 10,049,059 |
| LIABILITIES AND EQUITY | ||
| Revolving credit facility | 6,000 | 242,000 |
| Senior notes and other unsecured borrowings net | 4,018,608 | 4,014,011 |
| Accrued expenses and other liabilities | 347,860 | 352,549 |
| Total liabilities | 4,372,468 | 4,608,560 |
| Preferred stock $1.00 par value authorized 20,000 shares, issued and outstanding – none | — | — |
| Common stock $0.10 par value authorized 700,000 shares, issued and outstanding – 299,111 shares as of June 30, 2026 and 295,539 shares as of December 31, 2025 | 29,911 | 29,553 |
| Additional paid-in capital | 8,807,559 | 8,693,033 |
| Cumulative net earnings | 5,190,964 | 4,677,092 |
| Cumulative dividends paid | (8,696,011) | (8,297,416) |
| Accumulated other comprehensive income | 58,110 | 79,037 |
| Total stockholders’ equity | 5,390,533 | 5,181,299 |
| Noncontrolling interest | 251,760 | 259,200 |
| Total equity | 5,642,293 | 5,440,499 |
| Total liabilities and equity | 10,014,761 | 10,049,059 |
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net income | 538,244 | 252,539 |
| Adjustment to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 165,982 | 160,384 |
| Impairment on real estate properties | 392 | 15,450 |
| Straight-line rent and other write-offs | 9,762 | 27,537 |
| (Recovery) provision for credit losses | (8,313) | 321 |
| Amortization of deferred financing costs and loss on debt extinguishment | 6,808 | 2,396 |
| Stock-based compensation expense | 34,043 | 25,046 |
| Gain on assets sold net | (249,543) | (32,961) |
| Straight-line receivables | (23,015) | (23,526) |
| Interest paid-in-kind | (11,921) | (4,996) |
| Loss from unconsolidated entities | 2,284 | 3,066 |
| Other non-cash items | 8,599 | (4,358) |
| Change in operating assets and liabilities – net: | ||
| Contractual receivables | (1,786) | 1,059 |
| Other operating assets and liabilities | (38,312) | (740) |
| Net cash provided by operating activities | 433,224 | 421,217 |
| Cash flows from investing activities | ||
| Acquisition of real estate | (226,104) | (560,422) |
| Net proceeds from sale of real estate investments | 559,709 | 182,995 |
| Investments in construction in progress | (7,860) | (29,731) |
| Investment in loan receivables and other | (142,029) | (109,767) |
| Collection of loan principal | 209,087 | 100,297 |
| Investments in unconsolidated entities | (97,178) | (1,250) |
| Distributions from unconsolidated entities in excess of earnings | 6,688 | 1,466 |
| Capital improvements to real estate investments | (26,671) | (32,941) |
| Proceeds from foreign currency forward contracts | 978 | 4,675 |
| Receipts from insurance proceeds | 5,422 | 392 |
| Net cash provided by (used in) investing activities | 282,042 | (444,286) |
| Cash flows from financing activities | ||
| Proceeds from borrowings | 1,127,000 | 670,708 |
| Payments of borrowings | (1,363,000) | (527,240) |
| Payments of financing related costs | (333) | (6,540) |
| Net proceeds from issuance of common stock | 166,310 | 517,851 |
| Dividends paid | (398,445) | (383,785) |
| Redemption of Omega OP Units | (83,874) | (3,681) |
| Distributions to Omega OP Unit Holders | (32,478) | (26,056) |
| Net cash (used in) provided by financing activities | (584,820) | 241,257 |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | (800) | 5,661 |
| Increase in cash, cash equivalents and restricted cash | 129,646 | 223,849 |
| Cash, cash equivalents and restricted cash at beginning of period | 54,563 | 548,735 |
| Cash, cash equivalents and restricted cash at end of period | 184,209 | 772,584 |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except per share amounts); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗